Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Targeting the mevalonate pathway enhances the efficacy of 5-fluorouracil by regulating pyroptosis

Open access

Published version of a preprint

Abstract

The 5-fluorouracil (5-FU)-based chemotherapy regimen is a primary strategy for treating pancreatic cancer (PC). However, challenges related to 5-FU resistance persist. Investigating the mechanisms of 5-FU resistance and identifying a clinically viable therapeutic strategy are crucial for improving the prognosis of PC. Here, through clinical samples analysis, we found that the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme in mevalonate metabolism, is negatively correlated with the efficacy of 5-FU treatment. There is a significant correlation between HMGCR and the pyroptosis marker gasdermin D (GSDMD), and the HMGCR inhibitor simvastatin can significantly inhibit the activation of pyroptosis signaling. The exogenous addition of geranylgeranyl pyrophosphate (GGPP), a key metabolite of the mevalonate pathway, can significantly reduce sensitivity to 5-FU, and simvastatin combined with 5-FU demonstrates a strong synergistic effect. Furthermore, in organoid models and genetically engineered mice with spontaneous PC, the combination of simvastatin and 5-FU significantly inhibits tumor growth. In conclusion, our study reveals the critical role of the mevalonate pathway in 5-FU resistance and proposes a clinically feasible combination therapy strategy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12032-024-02557-5

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Abnormal activation of the mevalonate pathway promotes 5-FU resistance in PC. A-B Symbolic H&E staining and IHC staining of pathological tissues from PC patients, along with the IHC score. Results are presented as mean ± standard deviation. Student’s t test. ***P < 0.001. C Typical H&E and IHC staining of HMGCR and computed tomography scan in 5-FU-S and 5-FU-R patients. Yellow arrow, primary tumor; blue arrow, hepatic metastasis. D The correlation of OS and HMGCR expression level of patients treated with 5-FU. Kaplan–Meier analysis with log-rank test. HR, hazard ratio. E Multivariate Cox regression analysis of the prognosis in PC patients with FOLFIRINOX regimen, with 95% confidence intervals shown by the bars. F ROC curve illustrating the diagnostic accuracy of HMGCR expression levels in distinguishing 5-FU resistance among 56 patients with PC. G Analysis of the correlation between sex, age, AJCC staging, tumor differentiation, CA 19–9 value, and HMGCR levels in PC patients who have undergone treatment with the FOLFIRINOX regimen
Fig. 1 Abnormal activation of the mevalonate pathway promotes 5-FU resistance in PC. A-B Symbolic H&E staining and IHC staining of pathological tissues from PC patients, along with the IHC score. Results are presented as mean ± standard deviation. Student’s t test. ***P < 0.001. C Typical H&E and IHC staining of HMGCR and computed tomography scan in 5-FU-S and 5-FU-R patients. Yellow arrow, primary tumor; blue arrow, hepatic metastasis. D The correlation of OS and HMGCR expression level of patients treated with 5-FU. Kaplan–Meier analysis with log-rank test. HR, hazard ratio. E Multivariate Cox regression analysis of the prognosis in PC patients with FOLFIRINOX regimen, with 95% confidence intervals shown by the bars. F ROC curve illustrating the diagnostic accuracy of HMGCR expression levels in distinguishing 5-FU resistance among 56 patients with PC. G Analysis of the correlation between sex, age, AJCC staging, tumor differentiation, CA 19–9 value, and HMGCR levels in PC patients who have undergone treatment with the FOLFIRINOX regimenCC BY-NC-ND · PubMed Central
Fig. 2 Targeting the mevalonate pathway causes pyroptosis. A-B Symbolic H&E staining and IHC staining of pathological tissues from PC patients, along with the IHC score. Results are presented as mean ± standard deviation. Student’s t test. ***P < 0.001. C Representative IHC staining images of high and low levels of HMGCR and GSDMD. D The protein level correlation between HMGCR and GSDMD in patients with PC from our cohort (n = 56) using linear regression analysis. E–F Immunoblotting assay showing the protein level of pyroptosis marker protein in control (Ctr) and treatment (simvastatin, 5 μM) of PANC-1, Panc 02, and MIA PaCa-2. G-H Representative IF staining images and quantification on the induction of pyroptosis in MIA PaCa-2 cells by simvastatin and 5-FU, either alone or in combination. White arrow, the inflammasome. Results are presented as mean ± standard deviation. Student’s t test. ***P < 0.001
Fig. 2 Targeting the mevalonate pathway causes pyroptosis. A-B Symbolic H&E staining and IHC staining of pathological tissues from PC patients, along with the IHC score. Results are presented as mean ± standard deviation. Student’s t test. ***P < 0.001. C Representative IHC staining images of high and low levels of HMGCR and GSDMD. D The protein level correlation between HMGCR and GSDMD in patients with PC from our cohort (n = 56) using linear regression analysis. E–F Immunoblotting assay showing the protein level of pyroptosis marker protein in control (Ctr) and treatment (simvastatin, 5 μM) of PANC-1, Panc 02, and MIA PaCa-2. G-H Representative IF staining images and quantification on the induction of pyroptosis in MIA PaCa-2 cells by simvastatin and 5-FU, either alone or in combination. White arrow, the inflammasome. Results are presented as mean ± standard deviation. Student’s t test. ***P < 0.001CC BY-NC-ND · PubMed Central
Fig. 3 Simvastatin combined with 5-FU is synergistic. A-B The sensitivity to 5-FU and simvastatin in three PC cell lines. C-E After exogenous GGPP (10 μM) supplementation, the sensitivity to 5-FU in three PC cell lines. F-N The synergistic effect of 5-FU and simvastatin was evaluated by collaborative analysis model, and the synergistic concentration was measured respectively. O Cell viability analysis of PANC-1, Panc 02, and MIA PaCa-2 cells after treatment with different conditions for 72 h. Results are presented as mean ± standard deviation. Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 3 Simvastatin combined with 5-FU is synergistic. A-B The sensitivity to 5-FU and simvastatin in three PC cell lines. C-E After exogenous GGPP (10 μM) supplementation, the sensitivity to 5-FU in three PC cell lines. F-N The synergistic effect of 5-FU and simvastatin was evaluated by collaborative analysis model, and the synergistic concentration was measured respectively. O Cell viability analysis of PANC-1, Panc 02, and MIA PaCa-2 cells after treatment with different conditions for 72 h. Results are presented as mean ± standard deviation. Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001CC BY-NC-ND · PubMed Central
Fig. 4 5-FU combined with simvastatin significantly inhibited the organoid growth. A Graphical representation of the gene identification and organoid construction of KPC mouse model. B-C The synergy of 5-FU and simvastatin in the KPC organoid model was assessed, and the optimal concentration and synergy score were determined. D Representative images of the KPC organoids’ response to 5-FU and simvastatin (5-FU: 100 nM; simvastatin: 100 nM). E–H Relative growth rate, area, and diameter of KPC organoids’ response to 5-FU and simvastatin (n = 6). Results are presented as mean ± standard deviation. Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 4 5-FU combined with simvastatin significantly inhibited the organoid growth. A Graphical representation of the gene identification and organoid construction of KPC mouse model. B-C The synergy of 5-FU and simvastatin in the KPC organoid model was assessed, and the optimal concentration and synergy score were determined. D Representative images of the KPC organoids’ response to 5-FU and simvastatin (5-FU: 100 nM; simvastatin: 100 nM). E–H Relative growth rate, area, and diameter of KPC organoids’ response to 5-FU and simvastatin (n = 6). Results are presented as mean ± standard deviation. Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001CC BY-NC-ND · PubMed Central
Fig. 5 Targeting the mevalonate pathway combined with 5-FU significantly inhibited tumor progression. A Graphical representation of the treatment for KPC-derived allografts. B Tumor tissue photographs. (C-D) Tumor volume and weight statistics. E–F Representative H&E staining, IF staining (pan-keratin, Ki67), and IHC staining images of GSDMD in tumor tissue. G-H Quantification of pan-keratin, Ki67, and GSDMD staining in tumor tissue from KPC-derived allografts. I-J Kaplan–Meier analysis and tumor growth of KPC-derived allografts treated with 5-FU, simvastatin, or both. Results are presented as mean ± standard deviation (C, D, G, H, I). Student’s t test. **P < 0.01, ***P < 0.001
Fig. 5 Targeting the mevalonate pathway combined with 5-FU significantly inhibited tumor progression. A Graphical representation of the treatment for KPC-derived allografts. B Tumor tissue photographs. (C-D) Tumor volume and weight statistics. E–F Representative H&E staining, IF staining (pan-keratin, Ki67), and IHC staining images of GSDMD in tumor tissue. G-H Quantification of pan-keratin, Ki67, and GSDMD staining in tumor tissue from KPC-derived allografts. I-J Kaplan–Meier analysis and tumor growth of KPC-derived allografts treated with 5-FU, simvastatin, or both. Results are presented as mean ± standard deviation (C, D, G, H, I). Student’s t test. **P < 0.01, ***P < 0.001CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 5

Metadata

Authors
Xing, Z., Ma, Y., Jiang, X., Qing, H., Wu, Y., Che, S., Gao, Z., Wang, K., Wang, T., He, Q., Li, Z., Zhao, B., Liu, W., Sun, H., & Yu, Z.
Affiliations
Lanzhou University Second Hospital (CN)
Corresponding author
Yu, Zeyuan
Venue
Medical Oncology
Published
2024-11-20
Volume
42
Issue
1
Pages
9-9
ISSN
  • 1357-0560 (ISSN-L)
  • 1559-131X
OpenAlex
W4404540456
Cited by
4
References
42
Citations by year
2026: 3 · 2025: 1
FWCI
0.80
Type
journal article
Language
en
Open access
Licence
Locations
  • Medical Oncology (publishedVersion, cc-by-nc-nd)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Cuiying Scientific and Technological Innovation Program (CY2022-MS-A05)
  • National Natural Sciences Foundation of China (82360601)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
mevalonate pathway, 5-fluorouracil resistance, pancreatic cancer, pyroptosis, gasdermin D, HMGCR, simvastatin, geranylgeranyl pyrophosphate, combination therapy, chemotherapy synergy, tumor organoids
MeSH terms
Pyroptosis, Animals, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Drug Synergism, Female, Fluorouracil, Humans, Hydroxymethylglutaryl CoA Reductases, Male, Mevalonic Acid, Pancreatic Neoplasms, Polyisoprenyl Phosphates, Drug Resistance, Neoplasm, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the mevalonate pathway enhances the efficacy of 5-fluorouracil by regulating pyroptosis. https://app.cochat.ai/papers/10.1007/s12032-024-02557-5
The paper
Xing, Z., Ma, Y., Jiang, X., Qing, H., Wu, Y., Che, S., Gao, Z., Wang, K., Wang, T., He, Q., Li, Z., Zhao, B., Liu, W., Sun, H., & Yu, Z. (2024). Targeting the mevalonate pathway enhances the efficacy of 5-fluorouracil by regulating pyroptosis. Medical Oncology. https://doi.org/10.1007/s12032-024-02557-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.